This company listing is no longer active
Resumen de acción V9Z
Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
+ 2 riesgos adicionales
Competidores de Aceragen, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | €0.24 |
| 52 Week High | €11.09 |
| 52 Week Low | €0.24 |
| Beta | 1.2 |
| 1 Month Change | -64.96% |
| 3 Month Change | -84.00% |
| 1 Year Change | -97.16% |
| 3 Year Change | -99.14% |
| 5 Year Change | -99.82% |
| Change since IPO | -99.98% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| V9Z | DE Biotechs | Mercado DE | |
|---|---|---|---|
| 7D | -1.6% | -4.9% | -1.5% |
| 1Y | -97.2% | -19.9% | 0.9% |
Rentabilidad vs. Industria: V9Z underperformed the German Biotechs industry which returned -5.5% over the past year.
Rentabilidad vs. Mercado: V9Z underperformed the German Market which returned 10.9% over the past year.
Volatilidad de los precios
| V9Z volatility | |
|---|---|
| V9Z Average Weekly Movement | 30.6% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Precio estable de las acciones: V9Z's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: V9Z's weekly volatility (31%) has been stable over the past year, but is still higher than 75% of German stocks.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1989 | 26 | John Taylor | www.aceragen.com |
Resumen de fundamentos de Aceragen, Inc.
| Estadísticas fundamentales de V9Z | |
|---|---|
| Capitalización bursátil | €2.02m |
| Beneficios(TTM) | -€38.03m |
| Ingresos (TTM) | €6.79m |
0.3x
Ratio precio-ventas (PS)-0.1x
Ratio precio-beneficio (PE)¿Está V9Z sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de V9Z | |
|---|---|
| Ingresos | US$7.33m |
| Coste de los ingresos | US$15.40m |
| Beneficio bruto | -US$8.06m |
| Otros gastos | US$32.98m |
| Beneficios | -US$41.05m |
Últimos beneficios comunicados
Mar 31, 2023
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -4.88 |
| Margen bruto | -110.00% |
| Margen de beneficio neto | -559.86% |
| Ratio deuda/patrimonio | 1.3% |
¿Cómo se ha desempeñado V9Z a largo plazo?
Ver rendimiento histórico y comparativa